ReviewCancers2020
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 49 citations in OpenAlex.
- The role of IFNLR1 in modulating T cell infiltration and cancer progression in renal cell carcinoma.Journal of translational medicine · 2026Article
- Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based Combinations.Cancer reports (Hoboken, N.J.) · 2026Article
- The Multi-dimensional Mechanisms and Transformation Prospects of the Intratumoral Microbiota-Arginine Metabolism Axis in Tumor Progression and Immune Regulation.International journal of medical sciences · 2026Review
- Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma.Cancer cell · 2025Article
- AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma.Cell reports. Medicine · 2025Article
- Biomarker-informed care for patients with renal cell carcinoma.Nature cancer · 2025Review
- Refining the Tissue Source for Biomarker-based Approaches in Renal Cell Carcinoma.European urology · 2025Article
- Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment.Genome biology · 2024Article
- Research progress on the impact of intratumoral microbiota on the immune microenvironment of malignant tumors and its role in immunotherapy.Frontiers in immunology · 2024Review
- Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study.Human vaccines & immunotherapeutics · 2023Article
- Treatment Landscape of Renal Cell Carcinoma.Current treatment options in oncology · 2023Review
- Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment.bioRxiv : the preprint server for biology · 2023Article
- Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.Journal for immunotherapy of cancer · 2023Article
- The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma.BMC cancer · 2023Article
- BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.Cancer immunology, immunotherapy : CII · 2023Article
- Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma.Journal of clinical medicine · 2023Review
- Better prediction of clinical outcome in clear cell renal cell carcinoma based on a 6 metabolism-related gene signature.Scientific reports · 2023Article
- Artificial Intelligence in Renal Cell Carcinoma Histopathology: Current Applications and Future Perspectives.Diagnostics (Basel, Switzerland) · 2023Review
- When should surgery be used to supplement systemic therapy in metastatic renal cell cancer?Journal of thoracic disease · 2023Article
- Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.Nature reviews. Urology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy-based combinations, driven by PD-1, PD-L1, and CTLA-4 inhibitors, has altered the treatment landscape for metastatic renal cell carcinoma (RCC). Despite significant improvements in clinical outcomes, many patients do not experience deep or lasting benefits. Recent efforts to determine which patients are most likely to benefit from immunotherapy and immunotherapy-based combinations have shown promise but have not yet affected clinical practice. PD-L1 expression via immunohistochemistry (IHC) has shown promise in a few clinical trials, although variations in the IHC assays as well as the use of different values for positivity presents unique challenges for this potential biomarker. Several other candidate biomarkers were investigated including tumor mutational burden, gene expression signatures, single gene mutations, human endogenous retroviruses, the gastrointestinal microbiome, and peripheral blood laboratory markers. While individually these biomarkers have yet to explain the heterogeneity of treatment response to immunotherapy, using aggregate information from these biomarkers may inform clinically useful predictive biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.